rs754812132
Variant summary
Our verdict is Likely benign. The variant received -4 ACMG points: 1P and 5B. PP2BS1_SupportingBS2
The NM_001035.3(RYR2):c.3026G>A(p.Arg1009Gln) variant causes a missense change. The variant allele was found at a frequency of 0.0000217 in 1,613,850 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R1009P) has been classified as Uncertain significance.
Frequency
Consequence
NM_001035.3 missense
Scores
Clinical Significance
Conservation
Publications
- arrhythmogenic right ventricular dysplasia 2Inheritance: AD Classification: DEFINITIVE, NO_KNOWN Submitted by: Laboratory for Molecular Medicine, Ambry Genetics
- catecholaminergic polymorphic ventricular tachycardiaInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen, G2P
- catecholaminergic polymorphic ventricular tachycardia 1Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- hypertrophic cardiomyopathyInheritance: AD Classification: LIMITED Submitted by: ClinGen
- arrhythmogenic right ventricular cardiomyopathyInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -4 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| RYR2 | ENST00000366574.7 | c.3026G>A | p.Arg1009Gln | missense_variant | Exon 26 of 105 | 1 | NM_001035.3 | ENSP00000355533.2 | ||
| RYR2 | ENST00000661330.2 | c.3026G>A | p.Arg1009Gln | missense_variant | Exon 26 of 106 | ENSP00000499393.2 | ||||
| RYR2 | ENST00000609119.2 | n.3026G>A | non_coding_transcript_exon_variant | Exon 26 of 104 | 5 | ENSP00000499659.2 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152166Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.0000281 AC: 7AN: 249168 AF XY: 0.0000148 show subpopulations
GnomAD4 exome AF: 0.0000233 AC: 34AN: 1461684Hom.: 0 Cov.: 33 AF XY: 0.0000234 AC XY: 17AN XY: 727118 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152166Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74334 show subpopulations
ClinVar
Submissions by phenotype
not provided Uncertain:2
Has not been previously published as pathogenic or benign to our knowledge; Reported in ClinVar as a variant of uncertain significance (ClinVar Variant ID# 404229; Landrum et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not located in one of the three hot-spot regions of the RYR2 gene, where the majority of pathogenic missense variants occur (Medeiros-Domingo et al., 2009) -
p.Arg1009Gln in the RYR2 gene We have seen this variant in one person with DCM and SCA. Testing was sent to Invitae. Given the lack of case data we consider this variant to be of uncertain significance and we do not feel it is suitable for assessing risk in healthy relatives ("predictive genetic testing"). The variant has not been reported in the literature as of 10/2016. Per the Invitae report, "This sequence change replaces arginine with glutamine at codon 1009 of the RYR2 protein (p.Arg1009Gln). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and glutamine." The report also notes that the variant is predicted to be disruptive by in silico splicing and protein structure and function algorithms, but no functional data is available to confirm this. The Paralogue Annotation tool at cardiodb.org reports that no paralogue variants have been mapped to corresponding residues in related transcripts. The classification listed there is putative benign. The Arg1009Gln variant was reported online in 3 of 60,232 individuals in the Exome Aggregation Consortium dataset (http://exac.broadinstitute.org/), which currently includes variant calls on ~64,000 individuals of European, African, Latino and Asian descent (as of 10/3/2016). Specifically, the variant was observed in 2 of 5,767 Latino people (AF: 0.017%) and 1 of 4,893 African people (AF: 0.01%). The phenotype of those individuals is not publicly available. The dataset is comprised of multiple cohorts, some of which were recruited from the general population, others were enriched for common cardiovascular disease. Note that other variants with strong evidence for pathogenicity have been seen at similar frequencies in datasets like this so this does not necessarily rule out pathogenicity (Pan et al 2012). A different variant affecting the same codon, Arg1009Trp, which was reported online in 7 of 60,232 individuals in ExAC (as of 10/3/2016). Specifically, the variant was observed in 2 of 5,768 Latino people (AF: 0.017%), 1 of 4,313 East Asian people (AF: 0.017%), 1 of 8,213 South Asian people, and 3 of 33,306 non-Finnish European people. -
Catecholaminergic polymorphic ventricular tachycardia Uncertain:1
This missense variant replaces arginine with glutamine at codon 1009 of the RYR2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been performed for this variant. This variant has not been reported in individuals affected with cardiovascular disorders in the literature. This variant has been identified in 8/280576 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Cardiomyopathy Uncertain:1
This missense variant replaces arginine with glutamine at codon 1009 of the RYR2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with RYR2-related disorders in the literature. This variant has been identified in 8/280576 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Catecholaminergic polymorphic ventricular tachycardia 1;C1832931:Arrhythmogenic right ventricular dysplasia 2;C5542154:Ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome Uncertain:1
- -
Catecholaminergic polymorphic ventricular tachycardia 1 Uncertain:1
This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 1009 of the RYR2 protein (p.Arg1009Gln). This variant is present in population databases (rs754812132, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with RYR2-related conditions. ClinVar contains an entry for this variant (Variation ID: 404229). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on RYR2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Cardiovascular phenotype Uncertain:1
The p.R1009Q variant (also known as c.3026G>A), located in coding exon 26 of the RYR2 gene, results from a G to A substitution at nucleotide position 3026. The arginine at codon 1009 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at